Suppr超能文献

制定实施干预措施,并确定将健康创新融入常规实践的策略:以实施胰岛素患者决策辅助工具为例。

Developing an implementation intervention, and identifying strategies for integrating health innovations in routine practice: A case study of the implementation of an insulin patient decision aid.

机构信息

Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.

Department of Research, SingHealth Polyclinics, Singapore, Singapore.

出版信息

PLoS One. 2024 Nov 15;19(11):e0310654. doi: 10.1371/journal.pone.0310654. eCollection 2024.

Abstract

BACKGROUND

Implementation, which is defined as the process of getting evidence-based innovation to be utilised is critical in ensuring innovation is being integrated into real-world practice. The way an implementation intervention (i.e., a bundle of strategies to facilitate implementation) is developed has an impact on the types of strategies chosen, and whether they are relevant to the implementation setting to exert their effects. However, literature pertaining to development of intervention or detailed descriptions of implementation processes are scarce. This study aims to report the development of an implementation intervention to integrate the use of an evidence-based innovation in routine practice, using a Malaysian insulin patient decision aid (PDA) as an exemplar.

METHODS

The development of the insulin PDA implementation intervention was divided into two phases, incorporating step 3 and 4 of the Action Cycle in the Knowledge to Action framework. In Phase 1, barriers to the insulin PDA implementation was explored through qualitative interviews using an interview guide developed based on the Theoretical Domains Framework. In Phase 2, prioritisation of the barriers was conducted using the multivoting technique. Next, potential strategies that can address the barriers were identified based on understanding the clinic context, and evidence from literature. Then, the selected strategies were operationalised by providing full descriptions in terms of its actor, action, action target, temporality, dose, implementation outcome affected, before they were embedded into the patient care pathway in the clinic. The implementation intervention was finalised through a clinic stakeholders meeting.

RESULTS

In Phase 1, a total of 15 focus group discussions and 37 in-depth individual interviews were conducted with: healthcare policymakers (n = 11), doctors (n = 22), diabetes educators (n = 8), staff nurses (n = 6), pharmacists (n = 6), and patients (n = 31). A total of 26 barriers and 11 facilitators emerged and they were categorised into HCP, patient, organisational, and innovation factors. The multivoting exercise resulted in the prioritisation of 13 barriers, and subsequently, a total of 11 strategies were identified to address those barriers. The strategies were mandate change, training workshop, involve patients' family members or caretakers, framing/reframing, inform healthcare providers on the advantages of the insulin PDA use, define roles and responsibilities, place the insulin PDA in the consultation room, provide feedback, systematic documentation, to engage patients in treatment discussions, and juxtapose PDA in preferred language with patient's PDA in their preferred language to help with translation.

CONCLUSION

This study highlights main barriers to PDA implementation, and strategies that can be adopted for implementation. The steps for intervention development in this study can be compared with other intervention development methods to advance the field of implementation of evidence-based innovations.

摘要

背景

实施是将基于证据的创新应用于实践的过程,对于确保创新融入现实实践至关重要。实施干预措施(即促进实施的一系列策略)的开发方式会影响所选择策略的类型,以及这些策略是否与实施环境相关以发挥作用。然而,关于干预措施的开发或实施过程的详细描述的文献却很少。本研究旨在报告一种实施干预措施的开发,以将循证创新融入常规实践中,以马来西亚胰岛素患者决策辅助工具(PDA)为例。

方法

胰岛素 PDA 实施干预措施的开发分为两个阶段,将知识转化行动框架中的第 3 步和第 4 步纳入其中。在第 1 阶段,通过使用基于理论领域框架制定的访谈指南,通过定性访谈探索胰岛素 PDA 实施的障碍。在第 2 阶段,使用多投票技术对障碍进行优先级排序。接下来,根据对临床环境的了解和文献中的证据,确定可以解决障碍的潜在策略。然后,通过提供有关其参与者、行动、行动目标、时间性、剂量、受影响的实施结果的完整描述,将选定的策略纳入诊所的患者护理路径中。通过诊所利益相关者会议完成实施干预措施。

结果

在第 1 阶段,总共进行了 15 次焦点小组讨论和 37 次深入的个人访谈,参与者包括:医疗政策制定者(n=11)、医生(n=22)、糖尿病教育者(n=8)、护士(n=6)、药剂师(n=6)和患者(n=31)。共出现 26 个障碍和 11 个促进因素,并将其分为卫生保健提供者、患者、组织和创新因素。多投票练习导致 13 个障碍得到优先排序,随后确定了 11 项策略来解决这些障碍。这些策略包括:改变命令、培训研讨会、让患者的家属或照顾者参与进来、调整框架/重新调整框架、向医疗保健提供者介绍使用胰岛素 PDA 的优势、明确角色和责任、将胰岛素 PDA 放在咨询室、提供反馈、系统文档、让患者参与治疗讨论、将 PDA 翻译成首选语言并与患者的 PDA 翻译成他们的首选语言以帮助翻译。

结论

本研究强调了 PDA 实施的主要障碍和可以采用的实施策略。本研究中干预措施开发的步骤可以与其他干预措施开发方法进行比较,以推进循证创新的实施领域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46a1/11567623/a847c3b9f1bb/pone.0310654.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验